Mesalazine vanishing time from rectal mucosa following its topical administration

Journal of Crohn's and Colitis

Volumn 4, Issue 1, 2010, Pages 102-105

  Pimpo, M T ^b   Galletti, B ^a   Palumbo, G ^a   Viscido, A ^a   Gentile, P ^a   Caprilli, R ^a   Frieri, G ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

5 ASA; Pharmacokinetics; Ulcerative colitis

Indexed keywords

ENEMA; MESALAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FROZEN SECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM BIOPSY; RECTUM MUCOSA; REMISSION; STUDENT T TEST; TEMPERATURE; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; ENEMA; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MESALAMINE; PROCTOSCOPY; RECTUM;

EID: 75149131541     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.08.003     Document Type: Article

References (28)

1. Salazopyrin S.N. A new sulphanilamide preparation. A. therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestation in treatment with Sulfamilamide preparations. Acta Med Scand 110 (1942) 580-598
2. Khan A., Piris J., and Truelove S.C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2 (1977) 892-905
3. Frieri G., Giacomelli R., Pimpo M.T., Palumbo G., Passacantando A., Pantaleoni G., et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 47 (2000) 410-414
4. Frieri G., Pimpo M.T., Andreoli A., Annese V., Comberlato M., Corrao G., et al. Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Aliment Pharmacol Ther 13 (1999) 577-582
5. Frieri G., Pimpo M., Palumbo G., Onori L., Viscido A., Latella G., et al. Rectal and colonic mesalazine concentration in active ulcerative colitis: oral plus topical treatment. Aliment Pharmacol Ther 13 (1999) 1413-1417
6. Guarino J., Chatzinoff M., Berk T., and Friedman L.S. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: long-term results. Am J Gastroenterol 82 8 (1987) 732-737 Aug
7. Frieri G., Pimpo M., Galletti B., Palumbo G., Corrao G., Latella G., et al. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis 37 (2005) 92-96
8. Marshall J.K., and Irvine E.J. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 9 3 (1995) 293-300
9. Banerjee S., and Peppercorn M.A. Inflammatory bowel disease: medical therapy for specific clinical presentations. Gastroenterol Clin N Am 31 (2002) 185-202
10. Pokrotnieks J., Marlicz K., Paradowski L., Margus B., Zaborowski P., and Greinwald R. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther 14 9 (2000) 1191-1198 Sep
11. Marshall J.K., and Irvine E.J. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 95 (2000) 1628-1636
12. Regueiro M., Loftus E.V., Steinhart H., and Choen R.D. Clinical guidelines for the medical management of left sided? ulcerative colitis and ulcerative proctitis: summary statement. Infl Bow Disease 12 20 (2006) 972-978
13. Mantzaris G.J., Hatzis A., Petraki K., Spiliadi C., and Triantaphyllou G. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Col Rectum 37 1 (1994) 58-62 Jan
14. Yokoyama H., Takagi S., Kuriyama S., Takahashi S., Takahashi H., Iwabuchi M., et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 13 9 (2007) 1115-1120 Sep
15. Marteau P., Crand J., Foucault M., and Rambaud J.C. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 42 2 (1998) 195-199 Feb
16. Piodi L.P., Ulivieri F.M., Cermesoni L., and Cesana B.M. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol 39 2 (2004) 154-157 Feb
17. Truelove S.C., and Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 10 (1955) 41-48
18. Baron J.H., Connell A.M., and Lennard-Jones J. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1 (1964) 89-92
19. Palumbo G.C., Carlucci G., Mazzeo P., Frieri G., Pimpo M.T., and Fanini D. Simultaneous determination of 5-aminosalicylic acid, acetyl-5-aminosalicylic acid and 2.5-dihydroxybenzoic acid in endoscopic intestinal biopsy samples in humans by high-performance liquid chromatography with electrochemical detection. J Pharmacol Biomed Annal 14 (1995) 175-180
20. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 Suppl A (2005) 5-36
21. Campieri M., Lanfranchi G.A., Boschi S., Brignola C., Bazzocchi, Gionchetti P., et al. Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut 26 (1985) 400-405
22. Staerk Laursen L., Stokholm M., Bukhave K., Rask-Madsen J., and Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 31 (1990) 1271-1276
23. Aumais G., Lefebvre M., Tremblay C., Bitton A., Martin F., Giard A., et al. Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. Aliment Pharmacol Ther 17 1 (2003) 93-722 Jan
24. Naganuma M., Iwao Y., Ogata H., Inoue N., Funakoshi S., Yamamoto S., et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalazine and sulfasalazine. Inflamm Bowel Dis 7 3 (2001) 221-225
25. Jacobsen B.A., Abildgaard K., Rasnussen H.H., Christensen L.A., Fallingborg J., Hansen S.H., et al. Availability of mesalazine (5-Aminosalicylic acid) from enemas and suppositories during steady-state conditions. Scand J Gastroenterol 26 (1991) 374-378
26. Hussain F.N., Ajjan R.A., and Riley S. Dose loading with delayed-release mesalamine: a study of tissue drug concentration and standard pharmacokinetic parameters. Br J Clin Pharmacol 49 4 (2000) 323-330 April
27. Sandborn W.J., and Hanauer S.B. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 17 1 (2003) 29-42 Jan
28. Kane S., Huo D., Aikens J., and Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114 1 (2003) 39-43 Jan